Grise P, Mnif A, Navarra S, Foulatier O, Barret E, Sibert L, Pfister C
Service d'Urologie, Hôpital Charles Nicolle, Rouen.
Ann Urol (Paris). 1998;32(1):39-44.
Stilboestrol phosphate (ST 52) was evaluated on pain, general status, life expectancy and PSA, in a retrospective study of patients with prostatic carcinoma and relapse to hormonal treatment.
32 patients were treated by infusion of Stilboestrol phosphate at a daily escalating dose from 1.2 to 3 g over a period of 10 days, then subsequently oral administration.
Minor complications, especially nausea were observed in 12 cases but no major complication or interruption of treatment. Improvement for pain alone or with general status was obtained in 50% (16 cases) at 3 months, but at one year only 10% were still improved. Median survival was 8 months, with 19.4 months for responders at the end of infusions and 4.2 months for non-responders-respectively.
Stilboestrol phosphate can obtain a clinical response with low morbidity when relapse to hormonal treatment occurs. Infusion responders have a better life expectancy.
在一项对前列腺癌患者及激素治疗复发患者的回顾性研究中，评估磷酸己烯雌酚（ST 52）对疼痛、一般状况、预期寿命和前列腺特异性抗原（PSA）的影响。
32例患者接受磷酸己烯雌酚静脉输注治疗，剂量在10天内从每日1.2克逐步增至3克，随后改为口服给药。
12例患者出现轻微并发症，尤其是恶心，但未出现严重并发症或治疗中断情况。3个月时，仅疼痛或疼痛与一般状况均改善的患者占50%（16例），但1年后仍改善的患者仅占10%。中位生存期为8个月，输注结束时，有反应者的中位生存期为19.4个月，无反应者为4.2个月。
当激素治疗复发时，磷酸己烯雌酚可获得临床反应且发病率较低。输注有反应者的预期寿命更长。
